UNSPSC 51151531: Zifrosilone

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C11H13F3OSi, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6275788O83, chemically known as 2,2,2-trifluoro-3-(trimethylsilyl)acetophenone but generally known as zifrosilone, which bears US NIH Compound Identifier 60811. European Medicines Agency schedules Zifrosilone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00154MIG.

UNSPSC 51151531 Zifrosilone is a Commodity code that in practice covers naloxone and drug deactivation system procurement by state and local health agencies, based on recent solicitations that treat the code as a line item for emergency medical supplies and pharmaceutical products. State and local governments buy ready-to-deploy naloxone units and safe drug deactivation systems through this code to support community health, overdose response, and controlled substance management initiatives. The issuing bodies are health departments and state health and human services agencies, with Seminole County, Florida and the Texas Health and Human Services Commission appearing in recent activity.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking procurement of 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building at 520 W. Lake Mary Blvd, Sanford, FL 32771; the response deadline was July 26, 2023, and the contract carried a two-year initial term with a one-year renewal option on a fixed-fee basis, with vendors responsible for all shipping and delivery costs. The Texas Health and Human Services Commission issued Request for Information (RFI) HHS0017013 on April 3, 2026, to gather vendor capabilities and market intelligence about direct-to-manufacturer prescription fulfillment models for a Therapeutic Pharmacy Initiative, signaling early-stage state-level interest in alternative pharmacy supply chains and direct contracting approaches outside traditional pharmacy benefit managers and wholesalers. Both jurisdictions are in the South and Southwest; the code shows limited recent activity beyond these two opportunities and does not appear to generate routine high-volume state or local purchasing.